Objective To calculate the cost‐effectiveness of implementing Pl GF testing alongside a clinical
management algorithm in maternity services in the UK , compared with current standard …

… Objective: To determine the cost-effectiveness of the intra- and perilesional application of
recombinant human epidermal growth factor (rhEGF), as opposed to conventional therapy for …

… The incremental cost effectiveness was higher than €50,000/… The results confirmed the cost
effectiveness when simulating … analysis assessing the cost effectiveness of trastuzumab in …

… two strategies for treating metastatic human epidermal growth factor receptor 2–positive (HER2…
We assessed cost effectiveness by calculating the incremental cost-effectiveness ratio. In …

… Studies suggest nerve growth factor inhibitors (NGFi) relieve pain but may accelerate disease
… We sought cost and toxicity thresholds that would make NGFi a cost-effective treatment for …

… -analytic model to determine the cost-effectiveness of EGFR mutation testing and first-line …
to be cost-effective as a first-line treatment in Asia. We also assessed the cost-effectiveness of …

… therapy, erythropoietic growth factors maintain higher drug … This study estimated the
cost-effectiveness of growth factor … -based studies of growth factor therapy, previously published …

… growth factor receptor 2 (HER2) –overexpressing metastatic breast cancer. From the payer's
perspective of the United States and China, a cost-effectiveness … cost-effectiveness ratio, …

… Recent studies showed prolonged survival for advanced epidermal growth factor receptor
(EGFR)‐… Thus, we conducted this cost‐effectiveness analysis to explore an optimal first‐line …

… FISH testing was the most cost–effective strategy with an incremental cost–effectiveness ratio
of €12,245 per additional … Our model identifies FISH as the most cost–effective approach. …